Last month, UCB teamed up with Rebuilding Together®Silicon Valley, a non-profit organization committed to repairing homes for older Americans or people living with disabilities who are physically and financially unable to maintain safe living conditions.

We’re excited to be in Boston this week at the kickoff of the 25th 2018 BIO International Convention.

We are pleased to recognize two UCB leaders, Patty Fritz and Stephanie Hunter-Banks, who were recently appointed to leadership positions for Georgia healthcare industry groups: Georgia Bio and Healthcare Businesswomen’s Association (HBA), Atlanta Chapter, respectively. In support of our corporate strategy to create maximum value for patients, UCB is dedicated to encouraging diversity and inclusion. We are proud to celebrate the accomplishments of these two leaders who encourage and inspire the UCB colleagues around them.

Last year, the Secretary of Health and Human Services (HHS) appointed UCB’s Kristi Lengyel, Director of U.S. Patient Advocacy, to the National Institutes of Health (NIH) Task Force on Research Specific to Pregnant and Lactating Women (PRGLAC). 

By the time you finish reading the title of this post, a fragility fracture due to osteoporosis has occurred. It is estimated that a fragility fracture occurs every 3 seconds— totaling nearly 9 million fractures annually, worldwide. In the U.S. alone, fragility fractures are responsible for approximately 500,000 hospitalizations, 800,000 emergency room visits, and 180,000 nursing home placements each year.

This spring, UCB engaged the Atlanta community at the 2018 Atlanta Science Festival with a booth called “How the Canine Mind Helps People with Severe Diseases.” The festival is a two-week celebration of science offering more than 100 events at locations throughout metro Atlanta. UCB participated at the expo event held in Piedmont Park on March 24. 

Luiz Miguel Camargo, Ph.D., UCB’s Director of Innovation Networks, was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign talking about his work and dedication to advancing science to find solutions. 

Dr. Victor Sloan, UCB’s VP & Development Strategy Lead (immunology), was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign. Learn more about Dr. Sloan’s work and his motivation to find groundbreaking solutions.

Today, we announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),¹ an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

April is Parkinson’s Awareness Month. To honor those living with Parkinson’s disease (PD), we’re spreading awareness about the disease and sharing some of our favorite stories of inspiration.